These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22016502)

  • 61. Amphotericin B therapy in kala-azar.
    Giri OP
    J Indian Med Assoc; 1993 Apr; 91(4):91-3. PubMed ID: 8409490
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.
    Rijal S; Bhandari S; Koirala S; Singh R; Khanal B; Loutan L; Dujardin JC; Boelaert M; Chappuis F
    Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):225-9. PubMed ID: 19726065
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
    Lucero E; Collin SM; Gomes S; Akter F; Asad A; Kumar Das A; Ritmeijer K
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003699. PubMed ID: 25837313
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia.
    ter Horst R; Tefera T; Assefa G; Ebrahim AZ; Davidson RN; Ritmeijer K
    Am J Trop Med Hyg; 2009 Jun; 80(6):929-34. PubMed ID: 19478251
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.
    Thakur CP
    Int J Antimicrob Agents; 2001 Jan; 17(1):67-70. PubMed ID: 11137652
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M; Pavlotzky F; Barzilai A; Schwartz E
    J Am Acad Dermatol; 2013 Feb; 68(2):284-9. PubMed ID: 22858005
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Visceral leishmaniases].
    Rosenthal E; Marty P
    Rev Prat; 2004 Dec; 54(20):2211-6. PubMed ID: 15736529
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
    Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
    Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
    Davidson RN; di Martino L; Gradoni L; Giacchino R; Gaeta GB; Pempinello R; Scotti S; Cascio A; Castagnola E; Maisto A; Gramiccia M; di Caprio D; Wilkinson RJ; Bryceson AD
    Clin Infect Dis; 1996 Jun; 22(6):938-43. PubMed ID: 8783690
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
    Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
    Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
    Mullen AB; Baillie AJ; Carter KC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.
    Cota GF; de Sousa MR; Fereguetti TO; Rabello A
    PLoS Negl Trop Dis; 2013; 7(5):e2195. PubMed ID: 23658850
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epidemiology and spatiotemporal analysis of visceral leishmaniasis in Palestine from 1990 to 2017.
    Ahmad A
    Int J Infect Dis; 2020 Jan; 90():206-212. PubMed ID: 31704227
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar.
    Sundar S; Singh A; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2019 Oct; 101(4):795-798. PubMed ID: 31436156
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
    Berman J; Dietze R
    Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical aspects of visceral leishmaniasis in HIV infection.
    Jarvis JN; Lockwood DN
    Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.